NT 814

Drug Profile

NT 814

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer KaNDy Therapeutics; NeRRe Therapeutics
  • Class Small molecules; Vascular disorder therapies
  • Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sex hormone disorders; Vasomotor symptoms
  • Discontinued Opioid abuse

Most Recent Events

  • 07 Jun 2018 KaNDy Therapeutics plans the phase IIbSWITCH-1 trial for Vasomotor symptoms in 2018 (PO, Capsule) (NCT03596762)
  • 07 Jun 2018 Efficacy and adverse events data from the phase Ib/IIa RELENT-1 trial in Vasomotor symptoms released by KaNDy Therapeutics
  • 03 Oct 2017 Discontinued - Phase-II for Opioid abuse in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top